Is CLSD or JEPQ a better dividend investment in 2026?

CLSD currently yields 487.80% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: CLSD offers higher current income.

What is the dividend yield difference between CLSD and JEPQ?

CLSD has a forward dividend yield of 487.80% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 476.70 percentage points.

Home › Compare › CLSD vs JEPQ

CLSD vs JEPQ: Dividend Comparison 2026

CLSD yields 487.80% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CLSD wins by $50753.85M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CLSD

● Live price

487.80%

Share price

$0.41

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$50753.89M

Annual income

$36,168,404,531.85

Full CLSD calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — CLSD vs JEPQ

📍 CLSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CLSD	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CLSD + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CLSD pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSD

Annual income on $10K today (after 15% tax)

$41,463.41/yr

After 10yr DRIP, annual income (after tax)

$30,743,143,852.07/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, CLSD beats the other by $30,743,142,022.37/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSD + JEPQ for your $10,000?

CLSD: 50%JEPQ: 50%

100% JEPQ50/50100% CLSD

Portfolio after 10yr

$25376.97M

Annual income

$18,084,203,342.22/yr

Blended yield

71.26%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CLSD right now

CLSD

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-48.3

Piotroski

2/9

JEPQ

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSD buys

JEPQ buys

No recent congressional trades found for CLSD or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCLSDJEPQ

Forward yield	487.80% ✓	11.10%
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$50753.89M ✓	$44.8K
Annual income after 10y	$36,168,404,531.85 ✓	$2,152.59
Total dividends collected	$49478.61M ✓	$16.3K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: CLSD vs JEPQ ($10,000, DRIP)

Year	CLSD Portfolio	CLSD Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$59,480	$48,780.49	$11,930	$1,110.39	+$47.5K → CLSD
2	$334,811	$271,167.03	$14,133	$1,224.34	+$320.7K → CLSD
3	$1,784,770	$1,426,522.08	$16,632	$1,340.46	+$1.77M → CLSD
4	$9,016,553	$7,106,848.63	$19,454	$1,457.97	+$9.00M → CLSD
5	$43,202,271	$33,554,559.81	$22,626	$1,576.08	+$43.18M → CLSD
6	$196,483,123	$150,256,693.49	$26,175	$1,694.09	+$196.46M → CLSD
7	$848,895,486	$638,658,543.63	$30,133	$1,811.32	+$848.87M → CLSD
8	$3,487,095,949	$2,578,777,778.75	$34,531	$1,927.17	+$3487.06M → CLSD
9	$13,631,297,985	$9,900,105,319.66	$39,403	$2,041.08	+$13631.26M → CLSD
10	$50,753,893,375	$36,168,404,531.85	$44,787	$2,152.59	+$50753.85M → CLSD

CLSD vs JEPQ: Complete Analysis 2026

CLSD — Stock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Full CLSD Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this CLSD vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSD vs SCHD CLSD vs JEPI CLSD vs O CLSD vs KO CLSD vs MAIN CLSD vs XYLD CLSD vs QYLD CLSD vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.